RU2011133891A - СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА - Google Patents
СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА Download PDFInfo
- Publication number
- RU2011133891A RU2011133891A RU2011133891/15A RU2011133891A RU2011133891A RU 2011133891 A RU2011133891 A RU 2011133891A RU 2011133891/15 A RU2011133891/15 A RU 2011133891/15A RU 2011133891 A RU2011133891 A RU 2011133891A RU 2011133891 A RU2011133891 A RU 2011133891A
- Authority
- RU
- Russia
- Prior art keywords
- methylbutyrate
- hydroxy
- cytokines
- interleukin
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Способ лечения астмы у индивидуума, характеризующейся дисбалансом содержания цитокинов первого и второго типов, который включает введение индивидууму β-гидрокси-β-метилбутирата в количестве, эффективном для модуляции дисбаланса продукции цитокинов первого и второго типов.2. Способ по п.1, в котором отношение содержания цитокинов первого типа к содержанию цитокинов второго типа возрастает в результате введения β-гидрокси-β-метилбутирата.3. Способ по п.2, в котором содержание цитокинов первого типа возрастает без повышения содержания цитокинов второго типа.4. Способ по п.2, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.5. Способ по п.2, в котором β-гидрокси-β-метилбутират вводится в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.6. Способ по п.2, в котором цитокины типа 1 выбраны из группы, включающей интерферон y, интерлейкин 2 и интерлейкин 12, а цитокины типа 2 выбраны из группы, включающей интерлейкин 4, интерлейкин 5, интерлейкин 13 и интерлейкин 10.7. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для предотвращения уменьшения значения FEV.8. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для поддержания базового значения FEVвыше 80%.9. Способ по п.1, в котором цитокины типа 1 представляют собой интерфероны или интерлейкин 2, а цитокины типа 2 представляют собой интерлейкин 4.10. Способ лечения астмы у индивидуума, относящегося к группе риска в отношении развития астмы, включающий введение указанному индивид
Claims (15)
1. Способ лечения астмы у индивидуума, характеризующейся дисбалансом содержания цитокинов первого и второго типов, который включает введение индивидууму β-гидрокси-β-метилбутирата в количестве, эффективном для модуляции дисбаланса продукции цитокинов первого и второго типов.
2. Способ по п.1, в котором отношение содержания цитокинов первого типа к содержанию цитокинов второго типа возрастает в результате введения β-гидрокси-β-метилбутирата.
3. Способ по п.2, в котором содержание цитокинов первого типа возрастает без повышения содержания цитокинов второго типа.
4. Способ по п.2, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
5. Способ по п.2, в котором β-гидрокси-β-метилбутират вводится в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
6. Способ по п.2, в котором цитокины типа 1 выбраны из группы, включающей интерферон y, интерлейкин 2 и интерлейкин 12, а цитокины типа 2 выбраны из группы, включающей интерлейкин 4, интерлейкин 5, интерлейкин 13 и интерлейкин 10.
7. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для предотвращения уменьшения значения FEV1.
8. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для поддержания базового значения FEV1 выше 80%.
9. Способ по п.1, в котором цитокины типа 1 представляют собой интерфероны или интерлейкин 2, а цитокины типа 2 представляют собой интерлейкин 4.
10. Способ лечения астмы у индивидуума, относящегося к группе риска в отношении развития астмы, включающий введение указанному индивидууму эффективного количества β-гидрокси-β-метилбутирата.
11. Способ по п.10, в котором β-гидрокси-β-метилбутират вводят в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
12. Способ по п.11, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
13. Способ снижения риска развития инфекций у индивидуума пожилого возраста, относящегося к группе риска в отношении указанных инфекций, который включает введение указанному индивидууму эффективного количества β-гидрокси-β-метилбутирата.
14. Способ по п.13, в котором β-гидрокси-β-метилбутират вводят в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
15. Способ по п.14, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75225305P | 2005-12-19 | 2005-12-19 | |
| US60/752,253 | 2005-12-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A Division RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011133891A true RU2011133891A (ru) | 2013-02-20 |
Family
ID=38066532
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
| RU2011133891/15A RU2011133891A (ru) | 2005-12-19 | 2011-08-12 | СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8778992B2 (ru) |
| EP (2) | EP2082738B1 (ru) |
| JP (2) | JP5227182B2 (ru) |
| CN (2) | CN101374509B (ru) |
| AU (1) | AU2006331950A1 (ru) |
| BR (1) | BRPI0620083A2 (ru) |
| CA (1) | CA2632262C (ru) |
| CR (1) | CR10085A (ru) |
| EC (1) | ECSP088539A (ru) |
| ES (2) | ES2548305T3 (ru) |
| MY (1) | MY180733A (ru) |
| NZ (2) | NZ593182A (ru) |
| RU (2) | RU2469719C2 (ru) |
| SV (1) | SV2009002948A (ru) |
| TW (1) | TWI424840B (ru) |
| WO (1) | WO2007075605A2 (ru) |
| ZA (1) | ZA200805297B (ru) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| JP5227182B2 (ja) | 2005-12-19 | 2013-07-03 | アボット・ラボラトリーズ | １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用 |
| US9404924B2 (en) | 2008-12-04 | 2016-08-02 | Massachusetts Institute Of Technology | Method of performing one-step, single cell RT-PCR |
| CN102308213B (zh) | 2008-12-04 | 2014-10-29 | 麻省理工学院 | 诊断过敏性反应的方法 |
| US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| EP3403516A1 (en) * | 2008-12-09 | 2018-11-21 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9770424B2 (en) | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| EP2448425B1 (en) * | 2009-07-03 | 2018-09-05 | Nutreco Nederland B.V. | Animal feed or human food for improving intestinal barrier properties |
| RU2012125881A (ru) | 2010-01-29 | 2014-03-10 | Эбботт Лэборетриз | Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция) |
| US8916217B2 (en) | 2010-01-29 | 2014-12-23 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
| PE20121728A1 (es) * | 2010-01-29 | 2013-01-13 | Abbott Lab | Polvos nutricionales que comprenden hmb secado por aspersion |
| MX340405B (es) * | 2010-01-29 | 2016-07-07 | Abbott Lab | Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbut irato (hmb) de calcio y proteina soluble. |
| PE20121727A1 (es) * | 2010-01-29 | 2013-01-13 | Abbott Lab | Liquidos nutricionales en envases plasticos que comprenden beta-hidroxi-beta-metilbutirato (hmb) |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| TWI526161B (zh) * | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| CN103347406B (zh) | 2011-02-17 | 2015-08-05 | 雅培制药有限公司 | 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法 |
| CN102524332A (zh) * | 2011-12-19 | 2012-07-04 | 北京康比特体育科技股份有限公司 | 一种减肥压缩饼干及其制备方法 |
| CN104411305A (zh) * | 2012-03-19 | 2015-03-11 | 雅培制药有限公司 | 用于改善葡萄糖耐受的β-羟基-β-甲基丁酸 |
| WO2013188258A1 (en) * | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
| WO2014043685A1 (en) * | 2012-09-17 | 2014-03-20 | Abbott Laboratories | Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof |
| US20140272000A1 (en) * | 2013-03-14 | 2014-09-18 | Metabolic Technologies, Inc. | Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same |
| WO2014152606A2 (en) | 2013-03-14 | 2014-09-25 | Abbott Laboratories | Treatment of insulin resistance associated with prolonged physical inactivity |
| ES2625740T3 (es) * | 2013-03-15 | 2017-07-20 | Abbott Laboratories | Composiciones nutricionales que incluyen beta-hidroxi-beta-metilbutirato cálcico, fosfopéptido de caseina y proteina |
| ES2973467T3 (es) | 2015-09-16 | 2024-06-20 | Metabolic Tech Llc | Composiciones y métodos de uso de beta-hidroxi-beta-metilbutirato (HMB) para mejorar la recuperación de trauma de tejidos blandos |
| US12208073B2 (en) | 2015-09-16 | 2025-01-28 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MA49906A (fr) | 2017-08-14 | 2020-06-24 | Axcella Health Inc | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| JP7156683B2 (ja) * | 2018-09-28 | 2022-10-19 | 株式会社東洋新薬 | 経口組成物 |
| KR20230130600A (ko) * | 2020-06-15 | 2023-09-12 | 메타볼릭 테크놀로지스, 엘엘씨 | β-하이드록시-β-메틸부티레이트(HMB) 및 화학요법제의 조성물 및 사용 방법 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3408210A (en) | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
| US3542560A (en) | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
| GB1446965A (en) | 1974-02-14 | 1976-08-18 | Agricultural Vegetable Prod | Preparation of food products |
| US4104290A (en) | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
| US4311645A (en) * | 1980-03-24 | 1982-01-19 | Hoffmann-La Roche Inc. | Synthesis of SRS-active compounds |
| US4742081A (en) | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
| US4866040A (en) | 1986-01-06 | 1989-09-12 | Alfred Stracher | Aminocarnitine directed pharmaceutical agents |
| EP0367724B1 (en) | 1988-10-31 | 1993-02-10 | Sandoz Nutrition Ltd. | Improvements in or relating to organic compounds |
| US5000975A (en) | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
| CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| US5457130A (en) | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| US5087472A (en) | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
| US5028440A (en) | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| US4992470A (en) | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| US5167957A (en) | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
| US5601860A (en) | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
| FR2674102B1 (fr) | 1991-03-18 | 1994-05-20 | Meiji Seika Kaisha Ltd | Aliment pour porcs et methode d'elevage des porcs utilisant cet aliment. |
| US5171442A (en) | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
| US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| WO1994006417A1 (en) | 1992-09-16 | 1994-03-31 | Iowa State University Research Foundation, Inc. | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol |
| US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
| US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
| ES2105712T3 (es) | 1993-05-13 | 1997-10-16 | Loders Croklaan Bv | Sustitutivos de grasa de leche humana a partir de mezclas interesterificadas de trigliceridos. |
| US6136858A (en) | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
| US5444054A (en) | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| US5780451A (en) | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
| US5952314A (en) | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
| US5576287A (en) | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
| US5726146A (en) | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| KR0140248B1 (ko) | 1995-03-23 | 1998-06-15 | 한상기 | 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법 |
| DE19528461A1 (de) | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
| US5641531A (en) | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| US6165518A (en) | 1996-04-11 | 2000-12-26 | Loders Croklaan B.V. | Free flowing fat compositions |
| US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5756469A (en) | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
| US7504376B2 (en) | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| DE29707308U1 (de) | 1997-04-23 | 1997-06-26 | Kunz, Armin, 66450 Bexbach | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| US6103764A (en) | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
| US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
| JP4175698B2 (ja) | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| PT1100589E (pt) | 1998-07-30 | 2005-05-31 | Sigma Tau Ind Farmaceuti | Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena |
| US5976550A (en) | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
| US20010008641A1 (en) | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
| US6294206B1 (en) | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
| US6291525B1 (en) | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
| EP1221865B1 (en) | 1999-10-18 | 2007-01-03 | Muscletech Research and Development Inc. | Food supplement for increasing lean mass and strength |
| GB9929919D0 (en) | 1999-12-17 | 2000-02-09 | Hannah Research Inst The | Calcium phosphate nanoclusters and their applications |
| US6521591B1 (en) | 2000-02-10 | 2003-02-18 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
| US7250397B2 (en) | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| EP1268722A2 (en) | 2000-04-06 | 2003-01-02 | ConLinCo, Inc. | Conjugated linoleic acid compositions |
| JP4625156B2 (ja) | 2000-04-10 | 2011-02-02 | イーエヌ大塚製薬株式会社 | 癌化学療法に伴う副作用軽減剤 |
| US6420342B1 (en) | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US20050106219A1 (en) | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
| WO2002012436A2 (en) | 2000-08-03 | 2002-02-14 | North Carolina State University | Enhancement of development of oviparous species by in ovo feeding |
| US20030176514A1 (en) | 2000-08-29 | 2003-09-18 | Martin Fuhrmann | Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| US20030203070A1 (en) | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
| EP1198991B1 (en) | 2000-10-20 | 2012-12-19 | Nutriz N.V: | Non-dairy products derived from rice |
| CN1457357A (zh) | 2001-02-15 | 2003-11-19 | 旭电化工业株式会社 | 包含β－葡聚糖的制品 |
| JP3735070B2 (ja) | 2001-03-26 | 2006-01-11 | 花王株式会社 | 容器詰乳化飲料 |
| US6620427B2 (en) | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
| US20030021877A1 (en) | 2001-06-13 | 2003-01-30 | Cain Frederick William | Micronised fat particles |
| DE10145818C1 (de) | 2001-09-17 | 2002-10-10 | Alfill Engineering Gmbh & Co K | Sterilisiervorrichtung mit H202-Verdampfer |
| JP2003137790A (ja) | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−２，１（β２→β１）結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
| GB2381451A (en) | 2001-11-01 | 2003-05-07 | New Technology Res Ltd | Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect |
| US7419596B2 (en) | 2001-12-12 | 2008-09-02 | Martek Biosciences Corporation | Extraction and winterization of lipids from oilseed and microbial sources |
| US7168581B2 (en) | 2001-12-21 | 2007-01-30 | Rexam Medical Packaging Inc. | Closure for a retort processed container having a peelable seal |
| DE10163676A1 (de) * | 2001-12-21 | 2003-07-10 | Phenion Gmbh & Co Kg | Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose |
| ATE361910T1 (de) * | 2002-04-23 | 2007-06-15 | Aventis Pharma Inc | 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression |
| SE0201581D0 (sv) | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
| US20040013787A1 (en) | 2002-06-28 | 2004-01-22 | Theuer Richard C. | Fat compositions for infant formula and methods therefor |
| US20040048925A1 (en) | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| US20040106678A1 (en) | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
| WO2004035624A2 (en) | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| US7445807B2 (en) | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| US7332178B2 (en) | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
| FR2856596B1 (fr) | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
| WO2005035557A2 (en) | 2003-10-14 | 2005-04-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
| IL158555A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
| EP2002830A1 (en) | 2003-12-24 | 2008-12-17 | N.V. Nutricia | Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20050249650A1 (en) | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
| PL2238842T3 (pl) | 2004-09-09 | 2015-07-31 | Nestec Sa | Produkty odżywcze o ulepszonej jakości oraz sposoby i systemy ich dotyczące |
| US8557551B2 (en) | 2004-09-10 | 2013-10-15 | Dsm Ip Assets B.V. | Compositions and methods for making and modifying oils |
| PL371081A1 (pl) | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| US8067052B2 (en) | 2005-02-25 | 2011-11-29 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
| CA2537452C (en) | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
| RU2413430C2 (ru) | 2005-04-27 | 2011-03-10 | Энзимотек Лтд. | Композиция жировой основы (варианты) и способ ее получения (варианты), композиция заменителя жира женского молока и способ ее получения (варианты), смесь для детского питания |
| WO2006132968A1 (en) | 2005-06-06 | 2006-12-14 | Bristol-Myers Squibb Company | Low-phytate infant formulas |
| AU2006301389B9 (en) | 2005-08-26 | 2011-05-12 | Société des Produits Nestlé S.A. | Nutrition for obese patients |
| MY147363A (en) | 2005-09-20 | 2012-11-30 | Nestec Sa | Water dispersible composition and method for preparing same |
| WO2007066232A2 (en) | 2005-10-07 | 2007-06-14 | Ocean Nutrition Canada Ltd. | Salts of fatty acids and methods of making and using thereof |
| EP1973426A2 (en) | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
| JP5227182B2 (ja) | 2005-12-19 | 2013-07-03 | アボット・ラボラトリーズ | １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用 |
| CN101378669B (zh) | 2006-01-31 | 2012-10-10 | 雀巢技术公司 | 用于低出生体重儿的营养组合物 |
| US20080119552A1 (en) | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
| US20080194407A1 (en) | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
| US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| CA2649477C (en) | 2008-04-18 | 2016-04-19 | Nuvocare Health Sciences Inc. | Composition and method for promoting internal health and external appearance |
| CA2723441A1 (en) | 2008-05-21 | 2009-11-26 | Stokely-Van Camp, Inc. | Milk-based recovery beverage |
| EP3403516A1 (en) | 2008-12-09 | 2018-11-21 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| JP2009155336A (ja) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
| US20090312419A1 (en) | 2009-08-12 | 2009-12-17 | Kneller Bruce W | CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
| PL217815B1 (pl) | 2009-12-14 | 2014-08-29 | Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością | Napój izotoniczny z chelatami |
| CN101785566A (zh) | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动饮料 |
| RU2012125881A (ru) | 2010-01-29 | 2014-03-10 | Эбботт Лэборетриз | Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция) |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| US10869843B2 (en) | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
| EP2658535A1 (en) | 2010-12-27 | 2013-11-06 | Abbott Laboratories | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate |
| WO2012097061A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
| WO2013056048A2 (en) | 2011-10-13 | 2013-04-18 | Abbott Laboratories | Nutritional products comprising beta-alanine |
| WO2013170189A1 (en) | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
| WO2013188258A1 (en) | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
-
2006
- 2006-12-19 JP JP2008547409A patent/JP5227182B2/ja not_active Expired - Fee Related
- 2006-12-19 TW TW095147808A patent/TWI424840B/zh not_active IP Right Cessation
- 2006-12-19 ES ES09156851.9T patent/ES2548305T3/es active Active
- 2006-12-19 EP EP09156851.9A patent/EP2082738B1/en not_active Not-in-force
- 2006-12-19 BR BRPI0620083-4A patent/BRPI0620083A2/pt not_active IP Right Cessation
- 2006-12-19 CA CA2632262A patent/CA2632262C/en not_active Expired - Fee Related
- 2006-12-19 EP EP06845745.6A patent/EP1968564B1/en not_active Not-in-force
- 2006-12-19 US US11/641,978 patent/US8778992B2/en not_active Expired - Fee Related
- 2006-12-19 AU AU2006331950A patent/AU2006331950A1/en not_active Abandoned
- 2006-12-19 CN CN2006800479363A patent/CN101374509B/zh not_active Expired - Fee Related
- 2006-12-19 RU RU2008129605/15A patent/RU2469719C2/ru not_active IP Right Cessation
- 2006-12-19 ES ES06845745.6T patent/ES2548432T3/es active Active
- 2006-12-19 MY MYPI20082097A patent/MY180733A/en unknown
- 2006-12-19 NZ NZ593182A patent/NZ593182A/xx not_active IP Right Cessation
- 2006-12-19 WO PCT/US2006/048303 patent/WO2007075605A2/en not_active Ceased
- 2006-12-19 NZ NZ568611A patent/NZ568611A/en not_active IP Right Cessation
- 2006-12-19 CN CN2011100849630A patent/CN102225060A/zh active Pending
-
2008
- 2008-06-16 EC EC2008008539A patent/ECSP088539A/es unknown
- 2008-06-18 CR CR10085A patent/CR10085A/es unknown
- 2008-06-18 ZA ZA200805297A patent/ZA200805297B/xx unknown
- 2008-06-19 SV SV2008002948A patent/SV2009002948A/es unknown
-
2011
- 2011-08-12 RU RU2011133891/15A patent/RU2011133891A/ru not_active Application Discontinuation
-
2012
- 2012-01-11 US US13/347,750 patent/US8796333B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,774 patent/US20120177744A1/en not_active Abandoned
- 2012-01-11 US US13/347,757 patent/US20120178811A1/en not_active Abandoned
-
2013
- 2013-01-24 JP JP2013010874A patent/JP5696168B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011133891A (ru) | СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА | |
| Lönnerdal | Nutritional roles of lactoferrin | |
| Inagaki-Ohara et al. | Intestinal intraepithelial lymphocytes sustain the epithelial barrier function against Eimeria vermiformis infection | |
| DE60127457D1 (de) | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen | |
| Michele et al. | Vitamin supplements in the Era of SARS-Cov2 pandemic | |
| Aviles et al. | Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions | |
| Takagi et al. | Recombinant human growth hormone modulates Th1 and Th2 cytokine response in burned mice | |
| DD241271A5 (de) | Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro | |
| KR20200024940A (ko) | 의약품, 보충제 및 섭취된 물질의 생체 이용률을 향상시키기 위한 조성물 | |
| Sorkhabi et al. | Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19: biological and clinical plausibility | |
| EP4400098A3 (en) | Co-amorphous forms of beta-lactoglobulin and a drug substance | |
| Banerjee et al. | Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation | |
| Wu et al. | Major royal-jelly proteins intake modulates immune functions and gut microbiota in mice | |
| JP6675752B2 (ja) | 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤 | |
| JP3392668B2 (ja) | ゴマリグナン物質とビタミンｅ類の強化卵、強化卵の製造法、および強化卵に基づく健康食品 | |
| Wang et al. | Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway | |
| Sarker et al. | Keyhole limpet hemocyanin augmented the killing activity, cytokine production and proliferation of NK cells, and inhibited the proliferation of Meth A sarcoma cells in vitro | |
| ATE48759T1 (de) | Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen. | |
| US3347742A (en) | 2-(4-cyclohexylcyclohexyl)-3-hydroxy-1, 4-naphthoquinone in controlling coccidiosis in poultry | |
| Kobayashi et al. | Dietary supplementation of soybean kunitz trypsin inhibitor reduces lipopolysaccharide-induced lethality in mouse model | |
| JPH08503001A (ja) | 免疫組織および免疫反応強化化合物 | |
| Cameron et al. | Chronic hepatitis treated with methionine and choline | |
| CN109620823A (zh) | 一种Hypholomine B在制备免疫激活剂中的应用 | |
| DK1100463T3 (da) | Injicerbare formuleringer indeholdende ramoplanin | |
| Tamura et al. | Evaluation of recombinant human tumor necrosis factor by scheduled intratumoral administration in mice bearing transplantable tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140813 |